A report has revealed that the DNA records of more than 800 terror suspects have been wrongly deleted.Read the full story ›
The 100,000 Human Genomes Project is seeking volunteers to have their whole genomes sequenced. So what are the potential benefits and risks?Read the full story ›
Eleven NHS hospitals across England have been selected to begin recruiting 75,000 patients to have their genetic codes sequenced.
As part of the 100,000 Genomes Project, the 'Genomic Medicine Centres' (GMCs) will focus on patients with a rare disease and their relatives, and patients with cancer. The hospitals are:
- East of England NHS GMC
- South London NHS GMC
- North West Coast NHS GMC
- Greater Manchester NHS GMC
- University College London Partners NHS GMC
- North East and North Cumbria NHS GMC (will recruit patients with a rare disease only)
- Oxford NHS GMC
- South West Peninsula NHS GMC
- Wessex NHS GMC
- Imperial College Health Partners NHS GMC
- West Midlands NHS GMC
The Home Office has been accused of "shocking incompetence" for leaving a legal loophole that prevents police from holding the DNA profiles of thousands of suspected sex offenders.
From October, police in England and Wales will be banned from indefinitely holding genetic information on people arrested on suspicion of sexual and violent crimes once they have been released without charge.
Police will be given the right to apply for data to be held for longer, the BBC reported.
But with this appeal process not yet in place, Labour said many forces are already following government directives to delete records ahead of the change of law.
Shadow home secretary Yvette Cooper said: "Theresa May's failure to prevent and deal with this incompetence shows she has not taken seriously enough the risks to rape convictions and crime from her policy."
The Home Office said: "Forces will be able to retain DNA from someone arrested and not charged for up to three years, but only with permission from the biometrics commissioner. And all DNA samples taken by police are checked against the national database before deletion."
Knowing which genes are mutated in particular cancers could allow researchers to target those genes with specialised treatment.Read the full story ›
A Midlands company has helped develop a gun which fires pellets filled with artificial DNA that could help convict suspected rioters.Read the full story ›
Chief executive of The Institute of Cancer Research Professor Alan Ashworth, comments on the Tumour Profiling Unit's research that will look at the use of DNA mapping in future cancer treatments:
None of this is science fiction. One would think in five or 10 years this will be absolutely routine practice for every cancer patient, and that's what we're aiming to bring about.
Genetic profiling of cancer is already being investigated at several laboratories around the world, but the new unit will pioneer its use in the clinic
The £3 million Tumour Profiling Unit (TPU) in London is to research the use of DNA mapping to identify patients' cancer strains. It is hoped the technique will pave the way for radical new forms of diagnosis, surveillance and targeted therapy.
One aim of the research is to develop "liquid biopsies" that search for free-floating cancer DNA in samples of blood. This can then be used to identify and monitor cancer sub-types that are likely to respond to particular drugs.
Another, controversial, proposal is the use of "mouse avatars" that mirror a patient's disease progression.
Tumour samples from patients will be implanted into mice which will then be observed closely to spot early signs of molecular change and resistance to therapy.
A new laboratory could set the stage for a revolution in personalised cancer treatment in the coming decade, it has been claimed.
The £3 million Tumour Profiling Unit (TPU) in London aims to obtain the genetic map of an individual's tumours, enabling medical staff to give exactly the right drugs to tackle the disease.
Scientists will also use state-of-the-art techniques to track cancers as they progress, mutate and develop resistance to drugs.
The work, due to start this year, is expected to pave the way for radical new forms of diagnosis, surveillance and targeted therapy.
Patient trials are envisaged that will not only provide personalised treatments but follow the molecular development of tumours over time and combat drug resistance.